Several players, including small molecule company Inventiva, gastric balloon manufacturer Allurion Technologies, and even the American fitness organization The Beachbody Company all jumping on the GLP-1 bandwagon
The approval was based on the OASIS clinical trial programme and the SELECT cardiovascular outcomes trial, with the OASIS 4 study showing a mean weight loss of 16.6% at 64 weeks in adults with obesity or overweight, among participants who adhered to treatment
It means that sustainable results require either long-term medication use or significant lifestyle changes during treatment that persist after stopping
It is also approved as a mucolytic agent
L., Applebaum, J., Chicchi, G
Zhao S, Calvert L, Chang S, Arlinghaus RB, Guo JQ, Siciliano M, Riley R, Kantarjian H, Andreeff M